Quarterly report pursuant to Section 13 or 15(d)

Disposition (Details)

v3.5.0.2
Disposition (Details) - Biodefense Business [Member]
Nov. 04, 2015
USD ($)
shares
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]  
Sales of business, number of common stock shares eligible to receive | shares 23,008
Royalties receivable percentage on net sales 15.00%
Maximum [Member]  
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]  
Cash payments from Nanotherapeutics | $ $ 4,500,000